Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov;40(4):575-591.
doi: 10.1016/j.iac.2020.06.002. Epub 2020 Sep 9.

Biologics for the Treatment of Food Allergies

Kanwaljit K Brar  1 , Bruce J Lanser  2 , Amanda Schneider  3 , Anna Nowak-Wegrzyn  4
Affiliations
Review

Biologics for the Treatment of Food Allergies

Kanwaljit K Brar et al. Immunol Allergy Clin North Am. 2020 Nov.

Abstract

Food allergy is increasingly prevalent and poses a life-threatening risk to those afflicted. The health care costs associated with food allergies are also increasing. Current and emerging treatments for food allergies aim at protecting against reactions caused by accidental ingestion and increasing the food allergen reaction threshold, although this protection is often temporary. In the future, ideal biologic therapies would target key mediators of the type II immune pathway, essential in development of the atopic march to prevent development of food allergies. Biologics offering long-term protection against allergic reactions to food are needed, and several agents are already in development.

Keywords: Biologic; Cow’s milk; Food allergy; Monoclonal antibody; Omalizumab; Peanut.

PubMed Disclaimer

Conflict of interest statement

Disclosure K.K. Brar has received research support from Incyte Pharmaceuticals, and National Institutes of Health/National Institute of Allergy and Infectious Diseases–sponsored Atopic Dermatitis Research Network. B.J. Lanser reports serving as a consultant for Aimmune Therapeutics (peanut oral immunotherapy), Allergenis (food allergy diagnostics), GSK (medical education), Hycor (food allergy diagnostics), and Genentech (food allergy therapeutics). He is a speaker for Aimmune Therapeutics (peanut oral immunotherapy). He has received research support from Aimmune Therapeutics (peanut oral immunotherapy), DBV Technologies (peanut epicutaneous immunotherapy), and Regeneron Pharmaceuticals (food allergy therapy). He is a member of the National Institutes of Health/National Institute of Allergy and Infectious Diseases-sponsored Consortium for Food Allergy Research. A. Nowak-Wegrzyn is a member of the Data Monitoring Committee for the clinical trials of dupilumab for peanut allergy and has served on the advisory board for Genentech regarding omalizumab for food allergy as mono or combined therapy.

MeSH terms